← Back to Volume 6, Issue 7

Research Advances and Future Directions of Biotechnology in the Treatment of Myasthenia Gravis

Jiaqi Lin
Vol.6, No.7, pp.18-25, 2026 DOI: 10.62051/ijphmr.v6n7.03 August 28, 2026
Download PDF
Abstract: Myasthenia gravis (MG) is an autoimmune disease with a core pathological mechanism involving specific attacks by the immune system on proteins at the neuromuscular junction. This study reveals that our understanding of its pathogenesis has expanded beyond mere neuromuscular transmission dysfunction to encompass multiple aspects, including the dysregulation of immune regulatory networks, abnormal activation of the complement system, and damage mediated by specific autoantibodies. While conventional pharmacological therapies can alleviate clinical symptoms and control disease progression, they generally suffer from significant long-term side effects, substantial individual variability in patient response, and an inability to achieve a cure in most patients. In contrast, targeted biologics enable precise intervention in key disease pathways, whereas stem cell therapy and gene therapy offer novel strategies for restoring immune tolerance and achieving long-term functional control of the disease, collectively advancing the therapeutic paradigm from broad nonspecific immunosuppression toward precision medicine. This study reviews the pathogenesis of MG, systematically outlines the current applications of conventional drugs, targeted biologics, thymectomy, and gene therapy in its treatment, analyzes existing therapeutic challenges, and explores future directions, such as precision medicine and novel targeted therapies.
Keywords: Myasthenia gravis, Autoimmune diseases, Targeted biologics, Precision medicine, Gene therapy
APA Citation: Jiaqi Lin (2026). Research Advances and Future Directions of Biotechnology in the Treatment of Myasthenia Gravis. International Journal of Public Health and Medical Research, 6(7), 18-25. https://doi.org/10.62051/ijphmr.v6n7.03

References

  1. Doudna, J. A. (2020). The promise and challenge of therapeutic genome editing. Nature, 578(7794), 229–236. https://doi.org/10.1038/s41586-020-1978-5
  2. Gilhus, N. E. (2016). Myasthenia gravis. New England Journal of Medicine, 375(26), 2570–2581. https://doi.org/10.1056/NEJMra1602678
  3. Gilhus, N. E., Tzartos, S., Evoli, A., Palace, J., Burns, T. M., & Verschuuren, J. J. G. M. (2019). Myasthenia gravis. Nature Reviews Disease Primers, 5, 30. https://doi.org/10.1038/s41572-019-0079-y
  4. Howard, J. F., Jr., Bril, V., Vu, T., Karam, C., Peric, S., Margania, T., Murai, H., Bilinska, M., Shakarishvili, R., Smilowski, M., et al. (2021). Safety, efficacy, and tolerability of efgartigimod in patients with generalized myasthenia gravis (ADAPT): A multicenter, randomised, placebo-controlled, phase 3 trial. The Lancet Neurology, 20(7), 526–536. https://doi.org/10.1016/S1474-4422(21)00159-9
  5. Howard, J. F., Jr., Utsugisawa, K., Benatar, M., Murai, H., Barohn, R. J., Illa, I., Jacob, S., Vissing, J., Sommer, N., et al. (2017). Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalized myasthenia gravis (REGAIN): A phase 3, randomised, double-blind, placebo-controlled, multicenter study. The Lancet Neurology, 16(12), 976–986. https://doi.org/10.1016/S1474-4422(17)30369-1
  6. Narayanaswami, P., Sanders, D. B., Wolfe, G., Benatar, M., Cea, G., Evoli, A., Gilhus, N. E., Illa, I., Kuntz, N., et al. (2021). International consensus guidance for management of myasthenia gravis: 2020 update. Neurology, 96(3), 114–122. https://doi.org/10.1212/WNL.0000000000011124
  7. Rosenblum, M. D., Remedios, K. A., & Abbas, A. K. (2015). Mechanisms of human autoimmunity. Journal of Clinical Investigation, 125(6), 2228–2233. https://doi.org/10.1172/JCI78088
  8. Sanders, D. B., Wolfe, G. I., Benatar, M., Evoli, A., Gilhus, N. E., Illa, I., Kuntz, N., Massey, J. M., Melms, A., et al. (2016). International consensus guidance for management of myasthenia gravis. Neurology, 87(4), 419–425. https://doi.org/1212/WNL.0000000000002790
  9. Tzartos, S. J., & Lazaridis, K. (2020). Myasthenia gravis: Autoantibody specificities and their role in MG management. Frontiers in Neurology, 11, 596981. https://doi.org/10.3389/fneur.2020.596981
  10. Verschuuren, J. J. G. M., Palace, J., Murai, H., Tannemaat, M. R., Kaminski, H. J., Bril, V., Cea, G., et al. (2022). Advances and ongoing research in the treatment of autoimmune myasthenia gravis. The Lancet Neurology, 21(2), 189–202. https://doi.org/10.1016/S1474-4422(21)00379-3
  11. Wolfe, G. I., Kaminski, H. J., Aban, I. B., Minisman, G., Kuo, H. C., Marx, A., Ströbel, P., Mazia, C., et al. (2016). Randomized trial of thymectomy in myasthenia gravis. New England Journal of Medicine, 375(6), 511–522. https://doi.org/10.1056/NEJMoa1602489
  12. Yi, J. S., Guptill, J. T., Stathopoulos, P., Nowak, R. J., O’Connor, K. C., & Hehir, M. K. (2022). B cells in the pathophysiology of myasthenia gravis. Muscle & Nerve, 66(1), 7–17. https://doi.org/10.1002/mus.27564